SCHEMBL7737859

SCHEMBL7737859

CCCCn1ccc(-c2ccccc2OC)c(C(=O)O)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
PPARA Q07869 1/20 0.44
CNR2 P34972 7/20 0.44
CNR1 P21554 2/20 0.44
TLR8 Q9NR97 1/20 0.42
ICMT O60725 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
TNF P01375 2/20 0.40
PAX8 Q06710 1/20 0.40
GRM2 Q14416 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7734365 0.89 ICMT (0.45) MEN1KMT2ACNR2CNR1TLR8
SCHEMBL7736063 0.88 ALDH1A1 (0.42) MEN1KMT2APPARACNR2TNF
SCHEMBL7735552 0.85 BRD9 (0.40) MEN1KMT2APPARACNR2TNF
SCHEMBL7726010 0.84 TOP1 (0.41) MEN1KMT2AKDM4EHPGDHSD17B10
SCHEMBL7736232 0.82 TLR8 (0.49) CNR2CNR1TLR8ICMTGRM2
SCHEMBL7736088 0.81 PTGER4 (0.44) MEN1KMT2APPARAGRM2
SCHEMBL7735825 0.81 GFER (0.48) MEN1KMT2ATLR8GRM2KDM4E
SCHEMBL7735824 0.79 GRM2 (0.49) KMT2ACNR2CNR1TLR8ICMT
SCHEMBL7726016 0.77 EDNRA (0.42) GRM2
SCHEMBL7725865 0.75 MAPT (0.44) MEN1KMT2ACNR1GRM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK MEN1 1602/4885KMT2A 578/4885PPARA 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.